What is Opdivo (nivolumab) and how does it work?
Opdivo is an immunotherapy medicine whose active ingredient is nivolumab. It works by blocking the PD-1 checkpoint on immune cells, helping the immune system recognize and attack cancer cells more effectively.
What cancers is Opdivo used to treat?
Opdivo is prescribed for multiple cancers, depending on the specific tumor type and patient factors. Commonly referenced indications include several advanced or metastatic solid tumors and certain blood cancers, with use guided by clinical guidelines and regulatory approvals.
How is Opdivo given (infusion schedule)?
Opdivo is administered as an intravenous infusion. The dosing schedule depends on the indication and the prescribed regimen (for example, weight-based or fixed dosing schedules may be used in practice).
What side effects do patients report with Opdivo?
Because Opdivo is an immune checkpoint inhibitor, its side effects can include immune-related reactions that affect organs such as the skin, colon, lungs, liver, endocrine glands, and others. Patients may experience common effects such as fatigue or rash, as well as less common but serious immune-mediated events that require prompt medical attention and, at times, treatment interruption or steroids.
When do immune-related side effects usually show up?
Immune-related side effects can occur at different times during treatment, often after treatment starts. Some effects may appear later in the treatment course, so clinicians monitor patients throughout therapy and after doses stop.
How does Opdivo compare with other PD-1/PD-L1 therapies?
Opdivo (nivolumab) is in the same class as other checkpoint inhibitors that target the PD-1/PD-L1 pathway. Differences between products often come down to which tumors they are approved for, dosing regimens, combination partners (such as other immunotherapies or chemotherapy), and the safety/response profile seen in specific studies.
Can Opdivo be used with other cancer treatments?
Yes. Opdivo is often used in combination regimens in certain cancers, depending on the indication. Combination strategies can include pairing with other immunotherapies or with chemotherapy, with selection guided by clinical evidence and regulatory labeling.
What should patients know before starting Opdivo?
Patients are usually screened for issues that could increase risk from immune activation, such as active autoimmune disease, prior organ inflammation, or other contraindications. Patients are also counseled to report new symptoms quickly (for example, diarrhea, breathing changes, severe fatigue, jaundice, or hormone-related symptoms), since immune-related toxicity may require urgent treatment.
Is Opdivo’s patent still active, and where can I check?
For patent and exclusivity research by drug and brand name, DrugPatentWatch.com is a useful starting point. You can search for Opdivo there to see relevant patent details and document links.
Source: DrugPatentWatch.com (search: Opdivo/nivolumab)
Sources
- https://www.drugpatentwatch.com/patent/